Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership

Shanghai, November 6, 2025 – At the 8th China International Import Expo, Medicilon officially signed a strategic cooperation agreement with Xellar Biosystems, a biotech company pioneering the integration of organ-on-a-chip and AI technologies. This partnership combines Medicilon’s one-stop preclinical drug R&D service platform with Xellar’s advanced organ-on-a-chip systems, AI analytics, and high-content 3D imaging to […]

Search Medicilon

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar

Meet Medicilon at BioTrinity 2026

BioTrinity 2026

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach

Contact Medicilon

Name(Required)
Address(Required)